ALAMEDA, Calif.--(BUSINESS WIRE)--Science Corporation (“Science”), a leader in brain-computer interface (“BCI”) technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA (“Pixium”) of France, a bioelectronics BCI technology company..

加利福尼亚州阿拉米达市——（商业新闻短讯）——科学公司（“Science”）是脑机接口（“BCI”）技术的领导者和科学眼的开发者，已经收购了由法国生物电子BCI技术公司Pixium Vision SA（“Pixium”）开发的PRIMA视网膜植入物的IP和相关资产。

The transaction was announced in a Science blog post by CEO and co-founder Max Hodak, who said: “The PRIMA retinal implant, developed by Pixium and based on research done at Stanford University, shows great promise. The early clinical trial results we’ve seen are impressive. Together with the work being done at Science on the Science Eye, we now have two great opportunities to develop BCI technology for the potential restoration of vision in certain patients with severe vision loss.

首席执行官兼联合创始人马克斯·霍达克（Max Hodak）在一篇科学博客文章中宣布了这项交易，他说：“由皮修姆（Pixium）开发并基于斯坦福大学（Stanford University）的研究成果的PRIMA视网膜植入物显示出巨大的前景。我们看到的早期临床试验结果令人印象深刻。加上Science在科学之眼方面所做的工作，我们现在有两个很好的机会开发BCI技术，用于某些严重视力丧失患者的潜在视力恢复。

We are committed to bringing meaningful restoration of vision to patients as quickly as possible.”.

我们致力于尽快为患者带来有意义的视力恢复。”

Lloyd Diamond, outgoing CEO of Pixium, added: “I am thrilled to see our projects at Pixium going to Science, and in the hands of the outstanding scientists and engineers who are part of their team. I believe deeply in our past achievements and am grateful the PRIMA retinal implant will now have a home with people equally skilled and dedicated to helping patients.

即将离任的PixUIM首席执行官劳埃德·戴蒙德补充道：“我很高兴看到我们在PixUIM的项目走向科学，并掌握在他们团队中杰出的科学家和工程师手中。我对我们过去取得的成就充满信心，并感谢PRIMA retinal植入物现在将拥有一个拥有同样技能和致力于帮助患者的人的家。

I know they are committed to seeing this work through and am especially thankful for the people who are part of the clinical trials.”.

我知道他们致力于完成这项工作，并特别感谢参与临床试验的人。”

The acquisition was approved as part of a proceeding in the Paris Commercial Court, after Pixium was placed in liquidation. The terms of the deal were not announced.

在皮休姆被清算后，该收购被批准为巴黎商事法院诉讼的一部分。交易条款尚未宣布。

Pixium’s PRIMA system features a miniaturized, wireless, subretinal implant (originally developed at Stanford University) paired with a pocket computer, and glasses. Pixium has three ongoing clinical studies: two feasibility trials, in France and in the United States, as well as the PRIMAvera pivotal study (NCT04676854) in Europe, for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of age-related macular degeneration, for which up till now there is no treatment available..

皮修姆的PRIMA系统采用微型无线视网膜下植入物（最初由斯坦福大学开发），配以袖珍电脑和眼镜。Pixium有三项正在进行的临床研究：在法国和美国进行的两项可行性试验，以及在欧洲进行的PRIMAvera pivotal研究（NCT04676854），针对因年龄相关性黄斑变性的干萎缩形式引起的视网膜变性而导致严重视力丧失的患者，迄今为止尚无治疗方法。

The Science Eye, the company’s first flagship product in development, is a combination device that uses an optogenetic gene therapy targeted at the cells of the optic nerve (the retinal ganglion cells) in conjunction with an implanted flexible thin-film, ultra-dense micro-LED display panel inserted directly over the retina.

Science Eye是该公司正在开发的第一款旗舰产品，它是一种组合设备，使用针对视神经细胞（视网膜神经节细胞）的光遗传基因疗法，并结合植入的柔性薄膜超致密微型LED显示屏直接插入视网膜上。

The Science Eye is being developed for patients with serious blindness due to retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD), two forms of serious blindness without good options for patients..

科学眼是为患有色素性视网膜炎（RP）和干性年龄相关性黄斑变性（AMD）的严重失明患者开发的，这是两种严重失明的形式，患者没有良好的选择。

Science CEO Hodak continued: “Science is now developing advanced innovative products using two very different modalities. This transaction significantly expands our IP portfolio, and while we were strongly motivated in this acquisition by the potential of the PRIMA implant, we also felt that the patients enrolled in the Pixium clinical trials could not be left hanging.

Science首席执行官霍达克（Hodak）继续说道：“Science目前正在使用两种截然不同的方式开发先进的创新产品。这项交易大大扩展了我们的知识产权组合，虽然我们对PRIMA植入物的潜力有着强烈的动机，但我们也认为参加Pixium临床试验的患者不能悬而未决。

Now, we will be able to provide continuity and a future for the program. We look forward to working with them.”.

现在，我们将能够为该计划提供连续性和未来。我们期待着与他们合作。”

About Science Corporation:

关于科学公司：

Science Corporation develops advanced medical technologies at the frontier of our capabilities and understanding. As these technologies mature, they hold the potential to profoundly reshape the human condition. Today Science is focused on helping those with debilitating conditions for which there are no treatment options.

科学公司在我们的能力和理解的前沿开发先进的医疗技术。随着这些技术的成熟，它们具有深刻改变人类状况的潜力。今天，科学的重点是帮助那些没有治疗选择的衰弱患者。

Its first product in development, the Science Eye, deploys brain-computer interface technology with the goal of restoring vision to blind patients with retinitis pigmentosa and dry age-related macular degeneration. Headquartered in Alameda, California, the company also operates the Science Foundry, a MEMS foundry facility in Research Triangle Park, North Carolina..

其开发中的第一款产品“科学眼”部署了脑-计算机接口技术，旨在恢复患有色素性视网膜炎和干性年龄相关性黄斑变性的盲人患者的视力。该公司总部位于加利福尼亚州阿拉米达，还经营着科学铸造厂，这是一家MEMS铸造厂，位于北卡罗来纳州三角研究园。